Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | KYSE 410; KYSE410; Kyse410; KYSE0410 |
| Species | Human |
| Cat.No | ABC-TC1333 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Esophageal Squamous Cell Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Human Esophageal Cancer Cell Lines |
KYSE410 is a human esophageal squamous cell carcinoma (ESCC) cell line derived from a poorly differentiated, invasive tumor resected from a 51-year-old Japanese male patient. This epithelial-like cell line exhibits adherent growth in monolayers with a doubling time of approximately 45 hours. KYSE410 harbors mutations in TP53 and KRAS, and demonstrates overexpresses of oncogenic markers such as heparin-binding growth factor (hst-1) and cyclin D1. The cell line is tumorigenic in nude mice, readily forming subcutaneous tumors upon xenotransplantation. It retains key features of genomic instability, characteristic of advanced ESCC.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The KYSE410 cell line serves as a valuable in vitro model for studying pathogenesis and molecular biology of human esophageal squamous cell carcinoma. Its tumorigenic properties and defined mutational landscape make it particularly suited for investigating oncogenic signaling pathways, especially those involving TP53 and KRAS mutations. Researchers commonly utilize KYSE410 in preclinical drug screening, evaluating the efficacy of chemotherapeutic agents and targeted therapies, including inhibitors of EGFR and cyclin D1 pathways. Additionally, the cell line supports studies on tumor progression, metastasis, and resistance mechanisms, contributing to the development of novel therapeutic strategies for ESCC.
